Our Impact
“The most impactful aspect of our work has been the ability to share knowledge, information, and access with people worldwide. This effort has not only advanced CML education but also empowered many to enhance patient outcomes within their communities.” Professor Jorge Cortes - iCMLf Chairman
In 2024-2025...
106,000+ healthcare professionals reached worldwide
Strengthening expertise and decision-making across the global CML community
139 countries connected through iCMLf programs
Building a truly global network where knowledge is shared without borders
63% of participants from low- and middle-income countries
Closing the gap in access to specialist knowledge and expertise
978 hours of specialist CML education delivered
Equipping clinicians with the latest insights to improve patient outcomes
10,288 people accessed trusted online resources
Expanding access to reliable, evidence-based CML information
3,570 clinical trial resources accessed
Connecting clinicians and patients to research opportunities worldwide
Annual Report 2024-2025
Explore our latest progress and global impact in the 2024/25 iCMLf Annual Report, and see how we’re working together to improve the lives of people living with CML around the world.
Read now
Transforming CML Care in Ethiopia
When Dr. Amha Gebremedhin returned to Ethiopia, his hospital - the country’s largest - had no molecular testing for CML and limited treatment options. “We had the medications, but not the knowledge or tools to use them effectively,” he says.
Through the iCMLf’s ongoing support - including a transformative preceptorship with Professor Tim Hughes, access to expert guidance, resources, and clinical networks - Dr. Gebremedhin has reshaped CML care in Ethiopia. He launched one of the country’s first dedicated CML clinics, now serving over 2,500 patients, introduced molecular monitoring, expanded access to newer TKIs, and continues to train the next generation of hematologists.
“Our patients are living longer, healthier lives, and the iCMLf has walked with us every step of the way.”
Bringing New Hope to CML Patients in Nigeria
When Dr. Lanre Olatunde joined an iCMLf preceptorship in 2019, most CML patients in Nigeria only had access to imatinib or dasatinib - and few clinicians had hands-on experience with newer treatments.
“The preceptorship opened my understanding. I realised there could be better outcomes for patients I was seeing in Nigeria and in Africa in general,” she says.
Since then, with support and mentoring from the iCMLf, Dr. Olatunde has helped expand access to ponatinib and bosutinib, increased awareness of treatment options among colleagues, and regularly contributes to regional discussions to improve care across Africa.
“We can now access more lines of TKIs than before - and that simply wasn’t possible before... I’ve seen people who were once condemned now holding their grandchildren - the impact is not just on patients, it’s on families and whole communities.”